Imagin Nuclear Partners Receives Regulatory Approval from Medicare and Medicaid with Beth Israel and Manhattan Nuclear Partnership.NEW YORK -- Imagin Molecular Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :IMGM) announced today that Imagin Nuclear Partners (INP INP abbr. International News Photo ) a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Imagin Molecular Corporation has received regulatory approval to bill Medicare and Medicaid Medicare and Medicaid U.S. government programs in effect since 1966. Medicare covers most people 65 or older and those with long-term disabilities. Part A, a hospital insurance plan, also pays for home health visits and hospice care. for PET imaging services. This approval allows INP to image and service patients under Medicare and Medicaid programs at its affiliate site operating at Beth Israel Medical Center Beth Israel Medical Center is a hospital in New York City. It has four major locations providing health services. It acts as University Hospital and Manhattan Campus for the Albert Einstein College of Medicine of Yeshiva University. on Manhattan's lower east side. Joseph Oliverio, Chief Executive Officer stated that, "The notification of regulatory approval allows us to expand our target markets and offer our services through Beth Israel Medical Center to the more than 3,000,000 Medicare and Medicaid patients in and around New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . This is a significant step towards mass acceptance to our business plan and methodology. We have had great success through our physician affiliates working with government and private insurers in demonstrating that PET, as a first line test, saves money with better patient care and results compared to that of traditional coronary disease detection algorithms. We expect to duplicate our cost savings and patient outcome methodology in New York City which will allow us to compete for self-insured corporations and union contracts." About Imagin Molecular Corporation: Imagin Molecular Corporation strategy and focus is dedicated to business opportunities in positron emission tomography positron emission tomography: see PET scan. positron emission tomography (PET) Imaging technique used in diagnosis and biomedical research. (PET) manufacturing and the diagnosis of cancer, heart disease and neurological diseases. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. Imagin Molecular Corporation has positioned the Company to be a factor in PET and ancillary molecular imaging businesses. Imagin Molecular Corporation is also the Parent of Cipher Multimedia a new Media Marketing and Distribution Solution Company that provides a Distribution Solution for publishers of digital content. Cipher Multimedia will develop marketing campaigns that will assist Imagin, Positron Corporation and other companies market their products and will continue to provide publishers a distribution solution for digital content. About Imagin Nuclear Partners Imagin Nuclear Partners, a wholly owned subsidiary of Imagin Molecular Corporation, is a full-service joint venture molecular imaging partner that will own, operate and administer out-patient medical diagnostic imaging centers that utilizes PET and PET/CT PET/CT Positron Emission Tomography and Computed Tomography scanning equipment. Imagin Nuclear Partners specializes in using evidence based bioinformatics specifically positioned in the market to provide the maximal cost effective benefit to their joint venture partner and the community. For further information please contact Joseph Oliverio at Imagin Molecular Corporation at 630 371 5583 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion